Diversification of  T Cell Responses to Carboxy-terminal Determinants within the 65-kD Heat-shock Protein Is Involved in Regulation of Autoimmune Arthritis

por Moudgil, Kamal D., Chang, Tammy T., Eradat, Herbert, Chen, Audrey M., Gupta, Radhey S., Brahn, Ernest, Sercarz, Eli E.
Publicado 1997

Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan,...

por Young, Patricia A., Gaut, Daria, Kimaiyo, Davis K., Grotts, Jonathan, Romero, Tahmineh, Chute, John, Schiller, Gary, de Vos, Sven, Eradat, Herbert A., Timmerman, John
Publicado 2020

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor

por Wierda, William G., Byrd, John C., Davids, Matthew S., Furman, Richard R., Cheson, Bruce D., Barr, Paul M., Eradat, Herbert, Heffner, Leonard, Zhou, Lang, Verdugo, Maria, Potluri, Jalaja, Choi, Michael
Publicado 2018

Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial

por Montillo, Marco, Illés, Árpád, Robak, Tadeusz, Pristupa, Alexander S., Wach, Malgorzata, Egyed, Miklós, Delgado, Julio, Jurczak, Wojciech, Morschhauser, Franck, Schuh, Anna, Eradat, Herbert, Shreay, Sanatan, Barrientos, Jacqueline C., Zelenetz, Andrew D.
Publicado 2019

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

por Woyach, Jennifer, Flinn, Ian W., Awan, Farrukh, Eradat, Herbert, Brander, Danielle M., Tees, Michael, Parikh, Sameer, Phillips, Tycel, Ghori, Razi, Paydar, Ima, Farooqui, Mohammed Z. H., Byrd, John C., Stephens, Deborah
Publicado 2023

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma

por Topp, Max S., Eradat, Herbert, Florschütz, Axel, Hochhaus, Andreas, Wrobel, Tomasz, Walewski, Jan, Knopinska-Posluszny, Wanda, Kanate, Abraham S., Lech-Maranda, Ewa, Brunnberg, Uta, Chitra, Surya, Nielsen, Tina G., Sellam, Gila, Shivhare, Mahesh, Lossos, Izidore S.
Publicado 2022

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

por Mato, Anthony R., Wierda, William G., Davids, Matthew S., Cheson, Bruce D., Coutre, Steven E., Choi, Michael, Furman, Richard R., Heffner, Leonard, Barr, Paul M., Eradat, Herbert, Ford, Sharanya M., Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Byrd, John C.
Publicado 2019

P1125: DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA...

por Munoz, Javier, Locke, Frederick, Lekakis, Lazaros, Eradat, Herbert, Tees, Michael, de Vos, Sven, Nath, Rajneesh, Stevens, Don, Malik, Shahbaz, Popplewell, Leslie, Hamadani, Mehdi, Oluwole, Olalekan, Perales, Miguel-Angel, Miklos, David, Fisher, Paul, Goyal, Lovely, Navale, Lynn, Kaufman, Gregory, Kai, Kazuharu, Balakumaran, Arun, Neelapu, Sattva
Publicado 2023

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

por Sharman, Jeff P., Coutre, Steven E., Furman, Richard R., Cheson, Bruce D., Pagel, John M., Hillmen, Peter, Barrientos, Jacqueline C., Zelenetz, Andrew D., Kipps, Thomas J., Flinn, Ian W., Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R., Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O’Brien, Susan M., Stilgenbauer, Stephan
Publicado 2019

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician’s choice in cutaneous T-cell lymphoma: final data

por Horwitz, Steven M., Scarisbrick, Julia J., Dummer, Reinhard, Whittaker, Sean, Duvic, Madeleine, Kim, Youn H., Quaglino, Pietro, Zinzani, Pier Luigi, Bechter, Oliver, Eradat, Herbert, Pinter-Brown, Lauren, Akilov, Oleg E., Geskin, Larisa, Sanches, Jose A., Ortiz-Romero, Pablo L., Weichenthal, Michael, Fisher, David C., Walewski, Jan, Trotman, Judith, Taylor, Kerry, Dalle, Stephane, Stadler, Rudolf, Lisano, Julie, Bunn, Veronica, Little, Meredith, Prince, H. Miles
Publicado 2021

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

por Kim, Youn H., Prince, H. Miles, Whittaker, Sean, Horwitz, Steven M., Duvic, Madeleine, Bechter, Oliver, Sanches, Jose A., Stadler, Rudolf, Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Eradat, Herbert, Pinter-Brown, Lauren C., Ortiz-Romero, Pablo L., Akilov, Oleg E., Trotman, Judith, Taylor, Kerry, Weichenthal, Michael, Walewski, Jan, Fisher, David, McNeeley, Marise, Gru, Alejandro A., Brown, Lisa, Palanca-Wessels, M. Corinna, Lisano, Julie, Onsum, Matthew, Bunn, Veronica, Little, Meredith, Trepicchio, William L., Dummer, Reinhard
Publicado 2021